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Abstract The aim of this study was to investigate the
effects of beta-alanine supplementation on exercise
capacity and the muscle carnosine content in elderly sub-
jects. Eighteen healthy elderly subjects (60–80 years, 10
female and 4 male) were randomly assigned to receive
either beta-alanine (BA, n = 12) or placebo (PL, n = 6)
for 12 weeks. The BA group received 3.2 g of beta-alanine
per day (2 9 800 mg sustained-release Carnosyn
TM tab-
lets, given 2 times per day). The PL group received
2 9 (2 9 800 mg) of a matched placebo. At baseline
(PRE) and after 12 weeks (POST-12) of supplementation,
assessments were made of the muscle carnosine content,
anaerobic exercise capacity, muscle function, quality of
life, physical activity and food intake. A signiﬁcant
increase in the muscle carnosine content of the gastrocne-
mius muscle was shown in the BA group (?85.4%) when
compared with the PL group (?7.2%) (p = 0.004; ES:
1.21). The time-to-exhaustion in the constant-load sub-
maximal test (i.e., TLIM) was signiﬁcantly improved
(p = 0.05; ES: 1.71) in the BA group (?36.5%) versus the
PL group (?8.6%). Similarly, time-to-exhaustion in the
incremental test was also signiﬁcantly increased (p = 0.04;
ES 1.03) following beta-alanine supplementation
(?12.2%) when compared with placebo (?0.1%). Signiﬁ-
cant positive correlations were also shown between the
relative change in the muscle carnosine content and the
relative change in the time-to-exhaustion in the TLIM test
(r = 0.62; p = 0.01) and in the incremental test (r = 0.48;
p = 0.02). In summary, the current data indicate for the
ﬁrst time, that beta-alanine supplementation is effective in
increasing the muscle carnosine content in healthy elderly
subjects, with subsequent improvement in their exercise
capacity.
Keywords Acidosis  Buffering capacity 
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Introduction
Ageing is associated with both a loss of skeletal muscle
mass and skeletal muscle function leading to varying
degrees of sarcopenia as deﬁned by the European Working
Group on Sarcopenia in Older People (EWGSOP) (Cruz-
Jentoft et al. 2010). Changes include a decrease in the cross
sectional area of type II muscle ﬁbres (Verdijk et al. 2010)
as well as a loss of both type I and II muscle ﬁbres
(Doherty 2003), and a replacement of ﬁbres with fat.
Ageing is also associated with a signiﬁcant reduction in
skeletal muscle carnosine (Stuerenburg and Kunze 1999;
Tallon et al. 2007) resulting in a decline in the buffering
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DOI 10.1007/s00726-011-1190-xcapacity of the muscle. As a result elderly subjects may
experience a decrease in their capacity to undertake
anaerobic activity where this is limited by intramuscular
cell pH decrease (Stout et al. 2008). Combined with the
loss in muscle mass, progressive changes in muscle func-
tion will contribute to an increased sense of frailty in
elderly men and women with impairments in balance, gait
speed, and an increased risk of falls (Madureira et al.
2010). With the increase in longevity of industrialized
populations, sarcopenia is emerging as a major health and
ﬁnancial concern at the national level. Regular exercise,
incorporating some form of resistance training, is consid-
ered one of the most effective measures to slow, and even
reverse the progression of sarcopenia (Snijders et al. 2009;
Verdijk et al. 2009a, b).
Carnosine is a dipeptide synthesized in muscle and other
tissues involved in intracellular buffering and is composed
of the two amino acids histidine and beta-alanine (Artioli
et al. 2010). The availability of the is limiting to the in vivo
synthesis of carnosine under normal physiological condi-
tions (Harris et al. 2006). It has been previously shown that
supplementation with beta-alanine has the potential to
increase muscle carnosine content by 60–80% in healthy
young adults, and that this is accompanied by an
improvement in the ability to perform high-intensity
exercise (Harris et al. 2006; Hill et al. 2007; Kendrick et al.
2008, 2009).
Improving the buffering capacity of muscle could be
important for muscle function and daily-life activities in
the elderly. A previous study (Stout et al. 2008) dem-
onstrated a 28.6% increase in the physical working
capacity at the neuromuscular fatigue threshold after
90 days of beta-alanine supplementation (3 9 800 mg/
day) in men and women aged 55–92 years. The authors
suggested that the increase in working capacity could
have importance in the prevention of falls, and the
maintenance of health and independent living of elderly
men and women. However, the authors did not assess
muscle carnosine content. In fact, to the best of our
knowledge, no study has directly investigated the effect
of beta-alanine supplementation on the muscle carnosine
content in elderly individuals. It remains to be seen if
(a) muscle increases in carnosine can be achieved to a
similar extent as has been reported in younger subjects,
and (b) if any such increases can be correlated with
changes in exercise capacity.
Therefore, the aim of this study was to investigate the
effects of beta-alanine supplementation on exercise per-
formance capacity and the muscle carnosine content in
elderly subjects. It was hypothesized that beta-alanine
supplementation would increase the muscle carnosine
content in the elderly, which would be paralleled by an
increase in exercise capacity.
Materials and methods
Subjects
Eighteen subjects (60–80 years) who had not engaged in
any exercise programme for at least 1 year were recruited
to the study. Exclusion criteria were assessed by a physi-
cian and were as follows: joint disease or other causes of
limited mobility that would prevent the subject undertaking
the exercise tests, cardiovascular diseases which had not
been treated, the use of nutritional supplements within the
past 6 months (e.g., protein, amino acids and creatine), and
the use of any drug that could induce myopathy (e.g.,
simvastatin, glucocorticoid). Volunteers were instructed to
refrain from any exercise-training programme during the
course of the study.
The Local Ethical Committee approved the study and all
subjects gave their consent in writing after the purpose of
the study and the risks involved had been explained.
Experimental protocol
A double-blind, placebo-controlled study was conducted
between October 2010 and May 2011 in Sao Paulo
(Brazil).
Each participant was randomly assigned to either the
beta-alanine (BA, n = 12) or placebo (PL, n = 6) group
using a computer-generated randomization code. An
unbalanced design was adopted a priori to reduce the cost
of the trial and to gain more experience in using beta-
alanine supplementation in elderly subjects. The BA group
received 3.2 g of beta-alanine per day (2 9 800 mg sus-
tained-release Carnosyn
TM tablets, given 2 times per day
after lunch and dinner). The PL group received
2 9 (2 9 800 mg) placebo made up of maltodextrin,
which was identical in appearance. The supplements were
obtained from Natural Alternatives International, San
Marcos, USA. Carnosyn
TM and placebo tablets were from
the same batch as used by Sale et al. (2011) and were tested
by HFL Sports Science (Newmarket, UK) before use to
ensure no contamination with steroids or stimulants
according to ISO 17025-accredited tests. A researcher
called the subjects on daily basis to verify the compliance
to supplementation intake.
Muscle carnosine, anaerobic exercise capacity, muscle
function and quality of life were assessed at baseline (PRE)
and after 12 weeks (POST-12) of supplementation. All of
the subjects underwent one familiarization session prior to
the muscle function tests. Food intake was assessed at
baseline and after the intervention and physical activity
levels were assessed only at baseline. The closer moni-
toring of physical activity patterns and diet was not pos-
sible and it is a limitation of this study.
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123All the subjects were physically inactive (as assessed by
the international physical activity questionnaire—IPAQ)
(Voorrips et al. 1991) and well nourished (as assessed by
the Mini Nutritional Assessment (MNA) (Guigoz et al.
1994) at baseline and after the intervention. To characterize
the sample, measurements of body composition were also
assessed at PRE and POST-12 by Dual-energy X-ray
absorptiometry (DXA, Hologic QDR 4500, Discovery
model Bedford, MA, USA). Subjects’ demographic char-
acteristics are given in Table 1.
Muscle carnosine content
Muscle carnosine content was assessed in vivo by 1H-MRS
using a whole body 3.0-T MRI scanner (Achieva Intera,
Philips Best, the Netherlands) and an eight channel knee
coil. In brief, the calf muscle of the left leg was centred
within the knee coil ﬁxed with pads to avoid leg motion
during acquisition. Conventional anatomical T1-weighted
magnetic resonance images were obtained in three
orthogonal planes to select the voxel position in the gas-
trocnemius muscle for MRS measurements. Voxel size was
40 mm (I–S) 9 30 mm (A–P) 9 12 mm (L–R). Single-
voxel point-resolved spectroscopy sequence (PRESS) with
the following parameters was used: repetition time
(TR) = 2,000 ms; echo time (TE) = 31 ms; number of
repetitions = 256; 2,048 data points; spectral bandwidth of
2,000 Hz. Total acquisition time of the spectrum was
9 min. Spectra raw data were analysed with Java Magnetic
Resonance User Interface software (Naressi et al. 2001).
For quantiﬁcation purposes, only the carnosine H2 peak at
8.0 ppm was taken into account. Carnosine values were
normalized by the internal water content in the voxel,
measured from the water unsuppressed reference acquisi-
tions. Water and carnosine signals were quantiﬁed using a
Hankel–Lanczos singular value decomposition (HLSVD)
algorithm (Pijnappel et al. 1992). No corrections for the
effect of relaxation times were applied. The coefﬁcient of
variation (CV) for muscle carnosine content was 2.5%.
Carnosine data were expressed relatively to the water sig-
nal. The lack of a carnosine phantom (i.e., external refer-
ence) in the current study precluded us to quantify absolute
carnosine concentrations.
Physical capacity tests
The participants were required to visit the laboratory on two
occasions. At the ﬁrst visit, subjects performed an incre-
mental test on a motorized treadmill (Centurion 200, Micr-
omed, Brazil). The starting speed was set at 1.5 mph with
increments of 0.5 mph every min up to 3.5 mph; then slope
increments (2% increase every min) were made until
exhaustion. The ventilatory anaerobic threshold (VAT) and
VO2 peak were determined according to previously descri-
bed criteria (Howley et al. 1995). In the next session, the
subjectsperformed aconstant-load protocol on the treadmill
whichconsistedofa singlerepetitionsquare-wavetransition
fromresttoanexerciseintensitycorrespondingto75%ofthe
difference between VAT and VO2 peak. This intensity was
maintainedtothelimitoftolerance(TLIM).Inbothtests,the
time-to-exhaustion was assessed as a measure of exercise
tolerance. The subjects received strong verbal encourage-
ment to continue as long as possible.
Muscle function tests
Assessment of muscle function was through ‘‘timed-
stands’’ and ‘‘timed-up-and-go’’ tests. The ‘‘timed-stands’’
test (Newcomer et al. 1993) evaluates the maximum
number of stand-ups that a subject can perform from a
standard height (i.e., 45 cm) armless chair within 30 s and
the ‘‘timed-up-and-go’’ test evaluates the time that subjects
required to rise from a standard arm chair, walk to a line on
the ﬂoor 3 m away, turn, return, and sit down again, which
has been previously validated to measure improvements in
daily-life activities (Podsiadlo and Richardson 1991).
Quality of life assessment
The Brazilian version of the Short-Form Health Survey (SF-
36) was used to assess quality of life (Ciconelli et al. 1999).
The SF-36 consists of eight subscales: physical functioning,
role limitations due to physical health problems (so-called
physical role function), bodily pain, general health per-
ceptions, vitality, social role functioning, role limitations
due to emotional health problems (so-called emotional role
functioning) and mental health. Items were answered
according to standardized response choices. Raw scores are
Table 1 Subjects’ demographic characteristics at baseline
Beta-alanine (n = 12) Placebo (n = 6)
Gender (M/F) 6/6 2/4
Age (years) 65 ± 46 4 ± 7
Height (cm) 162 ± 11 162 ± 5
Body mass (kg) 78.2 ± 11.8 74.7 ± 12.4
BMI (kg/cm
2) 29.6 ± 2.7 28.4 ± 4.3
Body fat (kg) 25.9 ± 4.1 26.1 ± 6.8
Body fat (%) 33.4 ± 5.2 34.8 ± 8.2
LBM (kg) 50.1 ± 9.7 47.1 ± 10.1
BMD (g/cm
2) 1.1 ± 0.1 1.0 ± 0.1
BMC (kg) 2.1 ± 0.4 2.0 ± 0.2
Data are expressed as mean ± SD. There were no signiﬁcant differ-
ences between groups at baseline (p[0.05)
M males, F females, BMI body mass index, LBM lean body mass,
BMD body mineral density, BMC body mineral content
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123transformed to scale scores ranging from 0 to 100, with
higher scores indicating better levels of functioning.
Food intake assessment
Food intake was assessed at baseline and after 12 weeks of
supplementation by means of three 24 h dietary recalls
undertaken on separate days (2 weekdays and 1 weekend
day) using a visual aid photo album of real foods. The 24 h
dietary recall consists of the listing of foods and beverages
consumed during 24 h prior to the recall. Energy and
macronutrient intakes were analysed by the Brazilian
software DietPro 5.1 (Minas Gerais, Brazil).
Blood and urinary parameters
Blood and urine samples for clinical biochemistry (i.e.,
liver, muscle, kidney function tests) and haematology were
taken at PRE and POST-12 from all subjects.
Statistical analysis
Intention-to-treat analysis was used for each comparison,
irrespectiveofthecompliancewiththeintervention.Shapiro–
Wilk test revealed normal distribution of the data. Unpaired
ttestswereusedtoassessrelativechangesbetweengroupsfor
muscle carnosine and physical capacity parameters. Quality
of life data were tested by Wilcoxon test. The remaining
variables were tested by a Mixed Model procedure. Pearson
correlations were performed between relative changes in
musclecarnosinecontentandperformanceparameters.Effect
sizes (ES) for muscle carnosine and physical capacity
parameters were estimated for the posttest assessments using
thepooledstandarddeviationofthetwoindependentsamples
at POST-12 to determine the practical signiﬁcance of the
present ﬁndings. The signiﬁcance level was previously set at
p\0.05. Data are expressed as mean ± SD.
Results
According to the subjects’ self-reported compliance on
tablet intake, full adherence to the supplementation proto-
col was achieved. Three patients (two male and one female
from the BA group) presented unreliable MRS scans at
either PRE or POST-12 and were excluded from all anal-
yses involving muscle carnosine determination, and all
correlations. After exclusion of these subjects, baseline
values for all measurements remained non-signiﬁcantly
different between the groups. Body mass and body com-
position (data not shown), and food intake (Table 2) did
not signiﬁcantly differ within (between Pre and Post) or
between groups.
Muscle carnosine content
A signiﬁcant increase in muscle carnosine content was
shown in the BA group (?85.4%) when compared with the
PL group (?7.2%) (p = 0.004; ES: 1.21) (Fig. 1a, b).
Physical capacity
The time-to-exhaustion in the TLIM test was signiﬁcantly
improved (p = 0.05; ES: 1.71) in the BA group (PRE:
Table 2 Food intake at baseline and after 12 weeks following either
beta-alanine or placebo supplementation
Beta-alanine (n = 12) Placebo (n = 6)
PRE POST-12 PRE POST-12
Energy
(kcal/d)
2263 ± 332 2068 ± 513 2184 ± 409 2083 ± 352
Carbohydrate
%o f
energy
45 ± 74 4 ± 55 4 ± 54 6 ± 1
g/day 257 ± 55 228 ± 51 298 ± 23 238 ± 35
Fat
%o f
energy
38 ± 53 6 ± 43 1 ± 53 6 ± 1
g/day 96 ± 17 83 ± 20 76 ± 26 84 ± 15
Protein
%o f
energy
16 ± 32 0 ± 31 4 ± 11 8 ± 1
g/day 93 ± 25 103 ± 44 77 ± 20 94 ± 19
Data are expressed as mean ± SD. There were no signiﬁcant differ-
ences within or between groups
PRE baseline, POST-12 after 12 weeks of beta-alanine or placebo
supplementation
Fig. 1 a Individual data for muscle carnosine content (arbitrary
units) at baseline (PRE) and after 12 weeks of beta-alanine supple-
mentation (POST-12). b Relative change (%) in muscle carnosine
content (from PRE to POST-12). Asterisk indicates p\0.05 when
compared with the placebo group
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1235.2 ± 1.9, POST-12: 6.6 ± 1.7 min; 36.5%) versus the PL
group (PRE: 4.4 ± 1.1; POST-12: 4.7 ± 1.2 min; 8.6%)
(Fig. 2a). Similarly, the time-to-exhaustion in the incre-
mental test was signiﬁcantly increased (p = 0.04; ES:
1.03) following beta-alanine supplementation (PRE:
11.0 ± 2.1; POST-12: 12.1 ± 2.1 min; 12.2%) when
compared with placebo (PRE: 12.6 ± 1.7; POST-12:
12.5 ± 1.5 min; 0.1%) (Fig. 2b).
Asigniﬁcantandpositivecorrelationwasobservedbetween
the relative change in the muscle carnosine content and the
relative change in the time-to-exhaustion in the TLIM test
(r = 0.62; p = 0.01) and in the incremental test (r = 0.48;
p = 0.02). These correlations are illustrated in Fig. 3.
Muscle function
No signiﬁcant within- or between-group changes were
observed in the timed-stands test after beta-alanine sup-
plementation (PRE: 16 ± 2; POST-12: 17 ± 2 repetitions)
when compared with the PL group (PRE: 15 ± 3; POST-
12: 16 ± 3 repetitions). Similarly, no signiﬁcant changes
were observed in the timed-up-and-go test after beta-ala-
nine supplementation (PRE: 6.3 ± 0.8; POST-12:
6.2 ± 1.1 s) when compared with PL group (PRE:
6.3 ± 1.2; POST-12: 6.2 ± 1.1 s).
Quality of life
No signiﬁcant changes were observed between groups for
quality of life parameters (Table 3).
Blood and urinary parameters and side effects
Laboratory parameters were unchanged after the interven-
tion (Table 4). Additionally, there were no self-reported
side effects throughout the course of the study.
Discussion
The main and novel ﬁnding of the present study is that
beta-alanine supplementation is able to increase the muscle
carnosine concentration in elderly (60–80 yrs) subjects.
Importantly, the study also showed compelling evidence
indicating that the increase in muscle carnosine was par-
alleled by an improvement in exercise tolerance with no
evidence of any adverse effect. The present data is in
accordance with a growing body of evidence obtained in
Fig. 2 a Relative change (%) in total time of exercise during the
TLIM test (TLIM) from baseline to 12 weeks of beta-alanine
supplementation. b Relative change (%) in time to exhaustion during
the incremental test (TTE). Asterisk indicates p\0.05 when
compared with the placebo group
Fig. 3 a Correlation between the relative change (%) in the time-to-
exhaustion in the TLIM test and the relative change (%) in the muscle
carnosine content. b Correlation between the relative change (%) in
the time-to-exhaustion in the incremental test and the relative change
(%) in the muscle carnosine content
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123younger subjects suggesting that beta-alanine supplemen-
tation results in increased carnosine synthesis in muscle
(Harris et al. 2006; Hill et al. 2007). The present data
further demonstrate that within the age group measured,
ageing does not impair intramuscular beta-alanine uptake
or intramuscular carnosine synthesis.
Although one study (Kim 2009) demonstrated a normal
muscle carnosine content in older individuals with glucose
intolerance, Tallon et al. (2007) reported a 53% reduction
in carnosine in type II, but not in type I muscle ﬁbres, in
older subjects with osteoarthritis when compared with
younger healthy subjects. Similarly Stuerenburg and Kunze
(1999) reported a signiﬁcant age-related reduction in
skeletal muscle carnosine. These dissonant ﬁndings may be
explained, at least in part by dietary differences, as the
Korean population studied by Kim (2009) is described as
eating a typical Korean diet including chicken, pork and
beef meat, as well as ﬁsh. As noted by Kim (2009) Korean
cooking is typically done ‘‘in the pot’’ or by barbeque with
the result that loss of dipeptides is minimal. Changing
dietary patterns in the elderly due to loss of appetite will
reduce beta-alanine intake from the ingestion of histidine
containing dipeptides (carnosine, anserine and balenine).
Even where dietary intake of protein may be adequate,
dietary levels of beta-alanine may fall. Declining levels of
carnosine in muscle may also occur with preferential loss
of type II muscle ﬁbres with age, or with a reduction in
Table 3 Short Form Health Survey (SF36) data at baseline and after
12 weeks following either beta-alanine or placebo supplementation
Domain Beta-alanine
(n = 12)
Placebo (n = 6)
PRE POST-
12
PRE POST-
12
Physical functioning 74 ± 97 0 ± 13 61 ± 16 74 ± 7
Physical role functioning 16 ± 81 8 ± 61 1 ± 91 6 ± 5
Bodily pain 63 ± 18 71 ± 20 59 ± 13 61 ± 20
General health
perceptions
77 ± 14 82 ± 11 70 ± 13 72 ± 12
Vitality 73 ± 11 78 ± 12 59 ± 18 63 ± 17
Social role functioning 89 ± 16 91 ± 15 69 ± 19 73 ± 23
Emotional role
functioning
21 ± 72 2 ± 21 5 ± 71 4 ± 11
Mental health 79 ± 15 83 ± 97 5 ± 14 81 ± 16
Data are expressed as mean ± SD. There were no signiﬁcant differ-
ences within or between groups
PRE baseline, POST-12 after 12 weeks of beta-alanine or placebo
supplementation
Table 4 Biochemical
parameters and haematology at
baseline and after 12 weeks
following either beta-alanine or
placebo supplementation
Data are expressed as
mean ± SD. There were no
signiﬁcant differences within or
between groups
PRE baseline, POST-12 after
12 weeks of beta-alanine or
placebo supplementation,
AST aspartate amino
transferase, ALT alanine
aminotransferase, LDH lactate
dehydrogenase, CK creatine
kinase,
GGT glutamyltransferase
Beta-alanine (n = 12) Placebo (n = 6)
PRE POST-12 PRE POST-12
Aldolase (U/L) 3.4 ± 0.9 3.0 ± 1.2 4.0 ± 0.3 4.1 ± 0.7
CK (U/L) 141.7 ± 82.6 123.9 ± 65.2 117.0 ± 87.7 148. ± 107.0
ALT (U/L) 28.2 ± 15.0 26.7 ± 7.5 23.2 ± 6.6 23.0 ± 10.9
AST (U/L) 24.3 ± 7.0 22.6 ± 4.7 23.3 ± 2.1 21.8 ± 4.0
GGT (U/L) 29.00 ± 8.71 28.09 ± 7.54 17.83 ± 5.91 15.50 ± 5.82
Total bilirubin (mg/dL) 0.7 ± 0.2 0.6 ± 0.2 0.6 ± 0.1 0.6 ± 0.2
Glycemia (mg/dL) 109.7 ± 15.7 114.4 ± 17.9 89.0 ± 9.0 95.0 ± 8.4
LDH (U/L) 334.4 ± 34.4 323.2 ± 28.9 385.0 ± 35.7 401.7 ± 52.3
Urea (mg/dL) 37.58 ± 8.13 38.45 ± 7.09 35.67 ± 6.77 36.67 ± 9.46
Erythrocytes (1 million/mm
3) 4.94 ± 0.34 4.94 ± 0.31 4.82 ± 0.45 4.80 ± 0.53
Haemoglobin (g/dL) 15.05 ± 1.31 14.85 ± 1.09 15.05 ± 0.92 14.72 ± 1.09
Haematocrit (%) 44.33 ± 3.20 44.63 ± 2.50 44.30 ± 3.12 44.37 ± 3.17
Leukocytes (1,000/mm
3) 7.4 ± 1.6 7.5 ± 2.7 6.1 ± 1.0 6.6 ± 1.5
Neutrophils (1,000/mm
3) 3.9 ± 1.2 3.7 ± 1.5 3.0 ± 0.6 3.7 ± 1.5
Eosinophils (1,000/mm
3) 0.2 ± 0.1 0.5 ± 1.0 0.3 ± 0.2 0.2 ± 0.2
Basophils (1,000/mm
3) 0.01 ± 0.03 0.02 ± 0.04 0.02 ± 0.04 0.02 ± 0.04
Lymphocytes (1,000/mm
3) 2.6 ± 0.5 2.6 ± 0.8 2.2 ± 0.6 2.1 ± 0.8
Monocytes (1,000/mm
3) 0.6 ± 0.2 0.6 ± 0.2 0.6 ± 0.1 0.6 ± 0.1
Platelets (1,000/mm
3) 266.5 ± 59.8 261.0 ± 61.3 244.7 ± 35.8 253.0 ± 67.2
Urinary creatinine (g/L) 1.3 ± 0.6 1.2 ± 0.4 1.0 ± 0.8 0.9 ± 0.3
Creatinine (mg/dL) 0.9 ± 0.2 0.9 ± 0.1 0.9 ± 0.1 0.83 ± 0.2
Microalbuminuria (mg/L) 6.3 ± 3.2 6.7 ± 3.4 6.8 ± 6.5 4.5 ± 3.6
Proteinuria (g/L) 0.07 ± 0.05 0.08 ± 0.04 0.07 ± 0.05 0.07 ± 0.05
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123cross sectional area of type II muscle ﬁbres, since in
humans these have up to two times the level of carnosine
compared to type I (Harris et al. 1998; Hill et al. 2007). In
such circumstances beta-alanine supplementation could be
beneﬁcial in maintaining or even elevating muscle carno-
sine levels with possible improvements in physical exercise
capacity and life quality.
In the present study the mean increase of 85.4% in
muscle carnosine content after 12 weeks beta-alanine
supplementation was almost identical to the increase
observed after 10 weeks by Hill et al. (2007), albeit using a
dosing level twice that used in this study. Hill et al. (2007)
administered beta-alanine in a hard gelatin capsule, which
disintegrates rapidly on ingestion and gave rise to a peak in
the plasma concentration after 30 to 45 min. In the present
study a proprietary sustained-release tablet formulation
was used, which for the same dose results in a lower and
later peak plasma concentration and reduced urinary loss,
but generates the same area-under-the-plasma-concentra-
tion curve (Stellingwerff et al. 2011). By slowing the rate
of beta-alanine release, less is excreted in urine with a
greater percentage retained for carnosine synthesis in
muscle.
Importantly in the present study changes in TLIM and
TTE were positively correlated to the changes in muscle
carnosine. Similar correlations have been shown in
younger subjects with improved performances in cycling
(Hill et al. 2007) and rowing (Baguet et al. 2010)
tracking the increase in muscle carnosine content with
beta-alanine supplementation. Although Stout et al.
(2008) have earlier shown an improvement in the time to
neuromuscular fatigue in the elderly with beta-alanine
supplementation, the absence of carnosine measurements
did not enable comparison to any increase in the muscle
carnosine content. The emerging correlations in the
current study, between carnosine increase and exercise
performance, are consistent with the role of carnosine as
an intramuscular H
? buffer. In the context of the elderly,
those still active in such activities as cycling, skating,
mountain climbing, even gardening, as examples of
strenuous leisure activities involving bouts of intense
isometric and dynamic exercise, are likely to gain both
immediate beneﬁts from an increase in muscle carnosine,
as well as long-term beneﬁts if the current high level of
activity can be extended into more senior years. Whether
much less active older people are able to derive a similar
level of beneﬁt remains to be shown but many simple
tasks, for instance stair climbing, which in earlier years
might have been accomplished by aerobic exercise,
invoke increasing levels of anaerobic effort as muscle
mass progressively declines.
In the present study there were no improvements in the
‘‘timed-stands’’ and ‘‘timed-up-and-go’’ tests. Although
these have previously been validated to measure
improvements in daily-life activities (Podsiadlo and Rich-
ardson 1991, Newcomer et al. 1993) this is based on the
study of populations far less active than investigated here.
The lack of changes in the quality of life may be due to the
fact that subjects were healthy and functional at baseline. A
future goal, therefore, should be to study the effects of
beta-alanine supplementation in patients who are less
active and demonstrate a greater degree of sarcopenia and
frailty, and poor quality of life.
In any decade, whether it is 60?,7 0 ? or even 90?,
there will be a broad spectrum of activity levels set
against a background of declining musculo-skeletal
function. Moderating the rate of decline would help
maintain active participation in leisure activities and
independence. Regular exercise involving some form of
resistance training is considered the most effective
treatment in slowing the progression of sarcopenia
(Snijders et al. 2009; Verdijk et al. 2009a, b). We sug-
gest that beta-alanine supplementation by increasing the
capacity for resistance exercise and lessening the fatigue
burden associated with this, whether performed as part of
a prescriptive training programme, in the course of lei-
sure, or simply as part of normal everyday activities, will
encourage prolongation of an active life style in elderly
people. This assumption needs to be tested in future
studies.
In conclusion the present study indicates that beta-ala-
nine supplementation is effective in increasing the muscle
carnosine content in the elderly (60–80 years) with
improvements in physical exercise capacity. Beneﬁts in
maintaining a high muscle carnosine content may be both
immediate and long-term, if this encourages subjects to
maintain a more active life. Beta-alanine supplementation
possibly represents one of the few evidenced-based dietary
interventions which may help delay the decline in muscle
function with ageing.
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